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Abstract
Background: There is preliminary evidence linking physical activity to better prostate cancer 
(PCa) outcomes, though the molecular mechanisms underlying this association are not clear.
Methods: In a Seattle-based cohort of patients diagnosed with clinically localized PCa and 
prospective follow-up for outcomes (n=1354), we studied the association between self-reported 
vigorous physical activity and PCa progression to a metastatic-lethal phenotype. A subset of 
patients have prostate cancer tissue samples available for investigating DNA methylation 
(Infinium® HumanMethylation450 BeadChip array) and exercise (n=524).
Results: Patients who had vigorous physical activity at least once per week during the year 
before diagnosis (~79% of the cohort) were significantly less likely to progress to metastatic-lethal 
PCa compared to those who had vigorous physical activity less frequently (adjusted hazard ratio 
=0.63, p-value=0.029). Among the subset of men who had radical prostatectomy as primary 
treatment and tumor tissue available, a differentially methylated region (DMR) was identified 
(family-wise error rate=0.03, hypo-methylated in the weekly exercise group), with 9 methylation 
probes located in the promoter region of CRACR2A. This gene encodes a calcium binding protein 
involved in innate immune response. The methylation level of the nine CpGs was inversely 
correlated with CRACR2A gene expression (average correlation coefficient= – 0.35).
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Conclusions: Vigorous physical activity before diagnosis is associated with epigenetic 
alterations of CRACR2A and PCa metastatic lethal progression.
Impact: This analysis provides strong evidence for the association between vigorous physical 
activity and a less likelihood to develop metastatic lethal progression, and a suggestive link 
between exercise and DNA methylation in CRACRA2A gene.
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INTRODUCTION
Prostate cancer (PCa) is the most frequently diagnosed cancer among men in the United 
States (1–2). There are also close to 3 million prostate cancer survivors in the US, yet over 
27,000 men die each year from the disease (1–2). More than 80% of PCa patients are 
diagnosed with localized disease with excellent long-term survival. However, a subset of 
men with localized PCa will progress to develop metastasis and cancer-specific mortality. 
Among men diagnosed with clinically localized PCa, there is growing evidence linking 
physical activity with better outcomes (3–5), including a reduction in cancer progression (3), 
PCa-specific mortality (4–5), and all-cause mortality (4–5); however, the molecular 
pathways underlying these associations remain unclear. The hypothesized mechanisms 
include physical activity inducing alterations in circulating factors such as insulin-like grow 
factor I (IGF1), inflammatory cytokines and tumor vascularization that may inhibit 
proliferation and promote apoptosis of prostate cancer cells (6–9).
Numerous studies have been conducted to investigate exercise-induced molecular 
alterations, including DNA methylation in blood and some cancer tissues (10). While 
observational studies have reported weak correlations between physical activity and DNA 
methylation, interventional studies have consistently identified a significant impact of 
exercise on DNA methylation of a number of genes involved in metabolism, muscle growth 
and inflammation across different tissues (muscle, adipose, blood). This impact may depend 
on the genetic pathways involved, tissue-specificity, and intensity of exercise. The DNA 
methylation changes associated with exercise have not always correlated with changes in 
gene expression (10). For PCa, it has been observed that regular exercise improves patient 
outcomes. It is therefore of interest to investigate alterations of DNA methylation induced by 
exercise and explore potential beneficial effects of exercise that may be mediated by DNA 
methylation. One study reported that transcripts of cell cycle and DNA repair genes may be 
modulated in normal prostate tissue by vigorous activity (11). However, we are not aware of 
any studies that have focused on exercise and DNA methylation in primary PCa tissues.
We hypothesize that physical activity alters DNA methylation profiles in prostate tumor 
tissue, and these changes may be molecular intermediaries that lead to better PCa outcomes. 
To test this hypothesis we conducted a methylome-wide analysis in a cohort of men with 
localized PCa for whom self-reported vigorous physical activity data before diagnosis and 
long-term follow-up data for metastatic lethal progression were both available. The study 
aimed to investigate the relationship between vigorous physical activity and PCa metastatic 
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lethal progression, to identify differentially methylated positions (DMPs) and regions 
(DMRs) in prostate tumor tissue that are associated with vigorous physical activity, and to 
assess whether the changes in methylation, if any, were associated with corresponding 
changes in mRNA expression and metastatic lethal progression.
Materials and Methods
Study population
Participants of two previously described population-based studies of men with histologically 
confirmed, clinically localized PCa (n=1354) were included in the analysis (12–13). Men 
from the first study were diagnosed at ages 40 to 64 years during 1993–1996 and men from 
the second study were diagnosed at ages 35 to 74 years during 2002–2005. Information on 
demographics, medical history and environmental/lifestyle exposures up to and including the 
date of diagnosis was collected by in-person interviews occurring within 1 year after 
diagnosis (median elapse time from diagnosis to interview is 254 days), and men were asked 
for consent to access medical records and tumor tissue collected at biopsy and surgery. 
Vigorous physical activities were defined to be any type of leisure time activities that last 
more than 20 minutes or work up for a sweat in the questionnaire. Data collected on number 
of days in a week having vigorous physical activity in the year prior to PCa diagnosis were 
analyzed. Light and moderate activity data were not collected in one of the two studies and 
therefore not analyzed. Men were grouped into three categories of vigorous physical activity 
frequency in this analysis— greater than 3 times a week, 1–3 time a week, or <1 time per 
week vigorous physical activity. Gleason score, PSA at diagnosis, tumor stage, and primary 
treatment were collected from the SEER cancer registry. Prostate cancer recurrence status 
was determined from prospectively collected information from follow-up surveys, review of 
medical records, and/or physician follow-up as needed. Metastatic progression was 
confirmed by positive bone scan, MRI, CT, or biopsy. In this analysis, patients who 
developed metastases or died from prostate cancer were combined to a metastatic-lethal 
phenotype category. This study was approved by Fred Hutchinson Cancer Research Center’s 
Institutional Review Board, and all subjects signed informed consent.
Tumor sample preparation, methylation and gene expression profiling
Tumor sample collection was restricted to the subset of men who had radical prostatectomy 
as their primary treatment and for whom formalin-fixed paraffin-embedded (FFPE) 
prostatectomy specimens were available (n=566). FFPE blocks from radical prostatectomy 
specimens were used to make H&E slides, which were reviewed by a prostate pathologist to 
confirm the presence and location of PCa. Areas containing ≥75% tumor tissue were marked 
and two 1-mm cores were taken from the dominant cancer focus for DNA (using 
RecoverAll® Total Nucleic Acid Isolation Kit—Applied Biosciences) and RNA (RNeasy® 
FFPE Kit—Qiagen Inc.) purification.
Tumor DNA samples were bisulfite converted using the EZ DNA methylation kit (Zymo 
Research). The Infinium® Human Methylation450 BeadChip (Illumina) measured genome-
wide CpG methylation using beads with target-specific probes designed to interrogate 
>485,000 CpG sites (14). The correlations between blind duplicates ranged from 0.96 to 
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0.99, and were >0.99 for replicates across plates. Subset-quantile within array normalization 
(SWAN) (15) and batch adjustment through ComBat (16) were completed. After processing, 
methylation profiles on 478,998 CpG sites were available for 523 men. The DNA 
methylation β-value ranges from 0 (unmethylated) to 1 (fully methylated) as an estimate of 
the percentage of DNA in the tissue sample that is methylated at each CpG probe.
Matched tumor gene expression data for >29,000 transcripts were available for 469 (90%) 
men with methylation data. The Whole-Genome cDNA-mediated Annealing, Selection, 
extension and Ligation (DASL®) HT Assay (Illumina) developed specifically for use with 
archival FFPE specimens was used (17). Data were quantile normalized, log2 transformed 
and batch effects were removed using ComBat (16). The procedures for quality control and 
data processing have been described elsewhere (18).
Statistical methods
Descriptive statistics were used to summarize the demographic and clinical characteristics of 
patients stratified by weekly exercise frequency. Survival analysis and the Cox proportional 
hazards model were employed to assess the association between physical activity and the 
risk of metastatic-lethal progression, adjusting for relevant covariates. Covariates that may 
be associated with exercise were described in Table 1. A subset of these covariates who had 
p-value less than 0.1 in the Cox model were retained for adjustment, including age, smoking, 
education, study, Gleason sum, PSA level, and primary treatment. We identified individual 
differentially methylated positions (DMPs) by vigorous physical activity using linear 
regression coupled with empirical Bayes shrinkage as implemented in the Bioconductor 
limma package (19). We adjusted for body mass index, age at diagnosis, smoking history, 
race, and study. The differentially methylated region (DMR) analysis was conducted by the 
bumphunting method implemented in the Bioconductor Minfi package (20). We also 
evaluated whether the significant DMPs and DMRs were correlated with changes in mRNA 
expression of corresponding genes using Spearman correlations. Analyses were performed 
using R (https://www.r-project.org/).
RESULTS
The demographic and clinical characteristics of the 1354 patients with clinically localized 
PCa are shown in Table 1, stratified by the frequency of vigorous physical activity in the 
year prior to diagnosis (< 1 time per week or 1–3 times per week or > 3 times per week). 
Linear regression or Chi-square test of independence, when appropriate, were employed to 
assess univariate associations between these characteristics and three categories of vigorous 
physical activity (p-values not shown in Table1). Compared to the patients who had vigorous 
physical activity less than 1 time per week, the patient groups who had vigorous physical 
activity more than once weekly (including 1–3 times per week and >3 times per week) were 
more likely to have higher education level (bachelor degree or graduate school), less likely 
to be over-weighted (BMI>30), less likely to be current smoker. The median age of the 
group who exercised vigorously 1–3 times per week was 1 year younger than the other two 
exercise groups. The clinical characteristics of PCa, e.g. baseline PSA levels, Gleason sum, 
D’Amico risk score, did not differ significantly between the three exercise groups. Notably, 
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the proportion of patients who progressed to metastatic lethal phenotype was significant 
lower among patients who exercised vigorously more than once weekly (p-value=0.037), 
and no difference was shown between 1–3 times per week and >3 times per week (8% for 
both groups, Table 1).
The association of vigorous physical activity and metastatic lethal progression was assessed 
among the cohort of 1354 patients using a time-to-event analysis. A total of 128 metastatic 
lethal events were developed in follow-up. The median follow-up time since diagnosis is 
11.3 years. In a Cox proportional hazards model and when compared to the group with 
vigorous physical activity less than once per week, the hazard ratio of developing metastatic 
lethal progression is 0.56 for the group with 1–3 times per week (p=0.008), 0.64 for the 
group with >3 times per week (p=0.09), adjusting for age, smoking, education, study, 
Gleason sum, PSA level, and primary treatment. Since there is no material difference 
between the hazard ratios in the two exercise groups who exercised more than once per 
week, consistent with the results in Table 1, the two groups were combined in the coming 
analysis. Patients who exercised vigorously at least once weekly were consistently less likely 
to develop metastatic-lethal progression during follow-up (hazard ratio in the Cox model 
adjusting for the aforementioned covariates 0.63; 95% C.I. [0.42,0.95], p-value=0.029). 
When only adjusted for age at diagnosis, the hazard ratio for the association of weekly 
vigorous physical activity and metastatic-lethal progression is 0.57 (95% C.I. [0.39,0.84]). 
Figure 1 shows the Kaplan-Meier plot for time to metastatic-lethal event, stratified for the 
two exercise groups.
A subset of patients with localized prostate cancer who had radical prostatectomy as primary 
treatment and tumor samples available were analyzed by tumor DNA methylation profiling 
(n=524). Differential methylation probes were investigated using the Limma software in R/
Bioconductor. Figure 2(a) shows the quantile-quantile plot of p-values for ~450,000 probes 
that passed quality control. The majority of p-values reside on the diagonal line, suggesting 
that there is no systematic bias in the DMP analysis, though there are a few off-diagonal data 
points there is little evidence of significant DMPs. The minimal p-value among all probes 
being evaluated did not meet either the family-wise error rate or false discovery rate 0.05 
level. Figure 2(b) shows the volcano plot of p-values and the corresponding differences in 
methylation beta values between the two exercise groups, adjusting for age, smoking, race, 
study and a number of other potential confounders. The differences of methylation beta 
values between the two exercise groups range from −0.05 to 0.05.
The results of the differential methylated region (DMR) analysis are shown in Figure 3. The 
bumphunting method yielded over 4000 bumps (regions), though the majority of the bumps 
are not statistically significant after accounting for multiple testing. The top ranked DMR, 
which contains nine CpG probes in the promoter region of the CRACR2A gene on 
chromosome 12, reaches the family-wise error rate level <0.05 (Figure 3a). Patients who 
exercised vigorously at least weekly had approximately 10% lower methylation beta values 
at all nine CpG probes, compared to patients who exercised vigorously less than weekly 
(Figure 3b). These nine CpG probes are located from TSS 200 to 5’UTR and the first exon 
region (Table 2), with methylation levels inversely correlated with CRACR2A gene 
expression levels (correlation coefficient ~ −0.3). After adjusting for age, smoking and other 
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potential confounding covariates, the difference of beta values was smaller at the 5% level. 
The differences of beta values were less pronounced in the three CpG probes upstream in the 
TSS1500 region.
Table 3 shows the associations of the nine DMR probes in the CRACR2A gene with the time 
to metastatic-lethal progression, adjusting for the weekly vigorous physical activity. The 
analysis was conducted among the subset of patients with localized PCa who had 
methylation data available (n=463 men, 29 metastatic- lethal progression events). All nine 
probes show moderately significant hazard ratios with 10% decrease in methylation 
(0.80~0.88), some of which reach nominal statistical significance at p-value ≤0.05 level. The 
three most significant CpG probes associated with metastatic-lethal progression in Table 3 
are also significantly differentially methylated comparing the two exercise groups (Table 2). 
Because this analysis has been adjusted for vigorous physical activity, the results in Table 2 
and 3 rule out the possibility that physical activity may independently associated with the 
CpG probes and metastatic-lethal progression, suggesting the mediation role of these CpG 
methylation sites in the influence of physical activity on metastatic-lethal progression. The 
direction of the associations supports the hypothesis that more vigorous exercise promotes 
lower methylation levels in the promoter region of the CRACR2A gene, which in turn is 
associated with a lower risk of developing metastatic- lethal diseases.
DISCUSSION
In a well-characterized cohort of patients with localized PCa, men who exercised vigorously 
at least once per week during the year before diagnosis (~79% of the cohort) were 
significantly less likely to develop metastatic-lethal progression when compared to those 
who exercised vigorously but less frequently (HR=0.63, p-value=0.029). Vigorous physical 
activity was not associated with disease characteristics at diagnosis such as PSA level and 
Gleason sum. The time-to-analysis analysis was adjusting for potential confounding 
variables including age, smoking status, education, study, primary treatment method, 
Gleason sum. This result adds rigorous evidence to the existing literature on the association 
of vigorous physical activity and a lower likelihood to develop metastatic-lethal progression.
This analysis is the first to investigate the association between vigorous physical activity and 
DNA methylation in primary prostate tissues. While there is evidence for DMPs with 
exercise frequency in this methylome-wide search, no CpG probes reached genome-wide 
significance in single-probe analysis, likely due to high dimensionality of the CpG probes 
being investigated and limited sample size. The Bumphunting method, however, was able to 
combine regional probe-level associations and detected a differentially methylated region 
(DMR) (family-wise error rate=0.03) with nine methylation probes located in the promoter 
region of CRACR2A. All nine CpGs associated with higher exercise frequency had lower 
methylation levels (hypomethylation), which corresponded higher expression levels of the 
mRNA transcript. The differences in beta values are around 0.10, without adjusting for 
confounding variables. Furthermore, lower methylation levels of these CpGs were associated 
with reduced risk of developing metastatic- lethal progression during follow-up after 
adjusting for vigorous physical activity, supporting the hypothesis that differential 
methylation in the promoter region of CRACR2A may be part of the molecular 
Dai et al. Page 6
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
intermediaries reflected in the beneficial impact of vigorous physical activity on PCa 
metastatic-lethal progression. All these molecular and epidemiologic data corroborate with 
each other, supporting the mediation role of CRACR2A in exercise and PCa metastatic-
lethal progression. An independent validation study is warranted to confirm this molecular 
finding on mechanisms of vigorous physical activity influencing DNA methylation.
Calcium is an intracellular messenger essential for various biological processes including 
cell proliferation, apoptosis and metastasis. In non-excitable cells, store-operated calcium 
entry (SOCE) is the principle influx of Ca2+. CRACR2A is a gene encoding a calcium 
binding protein that is a key regulator of Ca2+ (CRAC) channels that mediate SOCE (21). 
This protein is involved in innate immune response and neutrophil degranulation, which may 
be associated with intense exercise. Similar observations include associations of a higher 
methylation level of CACNA2D3 gene, another calcium channel gene, with less exercise and 
worse prognostics of gastric cancers (22–23). As a ca2+ sensor, CRACR2A is highly 
expressed in T cells and play key roles in regulating SOCE. Evidence showed that 
CRACR2A directly interact with ORAI1 and STIM1, which are critical components of 
CRAC channels that regulate SOCE in immune cells, thereby forming a ternary complex. 
STIM1 locates in the endoplasmic reticulum (ER) as a Ca2+ sensor, it’s oligomerized with 
the cytoplasmic transmembrane protein ORAI1 to form pores for Ca2+ influx when the ER 
Ca2+ store is depleted. Inhibition of STIM1 or ORAI have been suggested to suppress cell 
proliferation, migration and invasion in various cancer models (24–28), including PCa (28). 
With the elevation of calcium ion concentration, CRACR2A would dissociate from ORAI1 
and STIM1, affecting their translocation and clustering. Based on our discovery, we 
speculate that CRACR2A could act as an upstream regulator of PCa progression through 
acting on STIM1 and ORAI1. Further experimental validation is needed to explore the 
molecular basis of this regulation.
The strengths of this study include a well-characterized PCa patient cohort with over 10 
years follow-up for cancer outcomes and the large number of patients having both genome-
wide methylation and gene expression data. The newly identified CpGs in the CRACR2A 
gene promoter show concerted associations with vigorous physical activity (hypo-
methylation) and RNA gene expression levels and the metastatic- lethal progression 
(reduced risk), consistent with the existing literature reporting hypo-methylation in Calcium 
channel genes associated with vigorous exercise and better prognostic outcomes. There are 
several limitations of this analysis. First, while the sample size for the patient cohort is over 
1000, on a subset of them have methylation profiling data available, proving a limited power 
to detect differential methylation in a genome-wide interrogation. Though interesting and 
plausible, the findings in the CRACR2A gene is exploratory and need to be validated 
separately. Second, the physical activity data were reported, harmonized between the two 
study cohorts. The recall bias and measurement error may cause a lack of finer 
categorization and dose association between the group who exercised vigorously less than 
weekly and the group who exercised vigorously more than once a week. We also did not 
have adequate data for analyzing light and moderate physical activities. The group which 
had vigorous physical activity less than once per week may contain some men with light and 
moderate physical activity, therefore may attenuate the estimates of the association 
parameters.
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Figure 1. 
Survival curve for developing metastatic-lethal progression in men diagnosed with clinically 
localized prostate cancer, stratify by the frequency of vigorous physical activity.
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Figure 2. 
Results of differentially methylated probe (DMP) analysis. The beta-values of methylation 
probes were regressed on weekly vigorous exercise frequency, adjusting for age, smoking, 
race, Gleason sum and other potential confounders. (a) The q-q plot of the p-values; (b) The 
volcano plot of p-values and differences of beta- values by vigorous physical activity.
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Figure 3: 
DMR results using the Bumphunting method. (a) Manhattan plot for the DMR p-values. The 
bump with the smallest p-value reaches a family wise error rate of 0.026 and contains nine 
probes for the CRACR2A gene. (b) The probe-level methylation beta-values for the 
identified DMR in the promoter region of the CRACR2A gene. The first nine probes are in 
the DMR.
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